黄斑水肿雷珠单抗对比玻璃体内抗炎治疗试验:葡萄膜炎性黄斑水肿再治疗24周结局
多中心随机对照试验纳入194例持续性或复发性葡萄膜炎性黄斑水肿患者(225只眼),按1:1:1随机接受地塞米松植入剂、甲氨蝶呤或雷珠单抗玻璃体内治疗。24周时按原分组分析地塞米松在改善黄斑水肿上优于雷珠单抗(CST 34% vs 19%,P=0.01),但与甲氨蝶呤无显著差异(31%,P=0.59);删失分析中仅地塞米松显示黄斑水肿和视力改善。
要点
- 24周按原分组分析:地塞米松CST改善34%优于雷珠单抗19%(P=0.01),与甲氨蝶呤31%无显著差异(P=0.59)。
- 删失分析中仅地塞米松与CST改善(34% vs 8%和5%,均P<0.001)及BCVA改善>5字母相关。
- 地塞米松更常出现眼压≥24 mmHg(32%)和≥30 mmHg(10%)。
核心结论
- 地塞米松在24周内治疗持续性或复发性葡萄膜炎性黄斑水肿比甲氨蝶呤和雷珠单抗更有效,副作用可控。
研究设计与样本
- 多中心随机对照临床试验,对视网膜厚度和视力进行掩蔽评估,共33个中心参与。
- 194例患者(225只合格眼)按1:1:1随机分配,分层因素为是否同时使用全身免疫抑制治疗葡萄膜炎,双眼黄斑水肿者双眼接受相同治疗。
- 随访24周,从12周起符合再治疗标准者允许接受非指定治疗。
主要发现
- 194例入组患者(225只眼)中,177例(207只眼)完成24周随访。
- 分配至甲氨蝶呤(55%)和雷珠单抗(37%)的眼比分配至地塞米松的眼(7%)更频繁接受非指定治疗(88%为地塞米松植入剂或玻璃体内皮质类固醇注射)。
- 按原分组分析中,地塞米松在改善黄斑水肿上优于雷珠单抗(CST 34% vs 19%,P=0.01),但与甲氨蝶呤无显著差异(CST 31%,P=0.59);12周时地塞米松曾优于另外两种方案。
- 删失分析中,仅地塞米松与黄斑水肿改善相关(CST 34% vs 甲氨蝶呤8%[P<0.001]和雷珠单抗5%[P<0.001])及BCVA改善>5字母相关。
- 地塞米松更常与眼压升高≥24 mmHg(32%)和≥30 mmHg(10%)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluation of longer-term effectiveness of 3 intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy (MERIT) Trial followed up for 24 weeks. DESIGN: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity. PARTICIPANTS: Patients with persistent or recurrent uveitic macular edema. METHODS: Participants from 33 centers were randomized 1:1:1 (stratified by presence or absence of concomitant systemic immunosuppression for uveitis) to receive a sequence of intravitreal treatments with dexamethasone implant, methotrexate, or ranibizumab. Participants with bilateral macular edema received the same treatment bilaterally. During 24 weeks of follow-up, nonassigned treatments were permitted beginning from 12 weeks for those meeting re-treatment criteria. MAIN OUTCOME MEASURES: Central subfield thickness (CST) change from baseline OCT measurement was the main outcome. Secondary outcomes included change in mean standard letters of baseline best-corrected visual acuity (BCVA). Analyses were conducted according to 2 principles: (1) as assigned, in which outcomes were analyzed according to their original randomized treatment, and (2) a supplementary censored analysis, in which data were excluded after an eye received a nonassigned treatment. RESULTS: Among 194 enrolled participants (225 eligible eyes), 177 participants (207 eyes) completed 24 weeks of follow-up. Eyes assigned to methotrexate (55%) and ranibizumab (37%) more frequently received nonassigned treatments (88% dexamethasone implant or intravitreal corticosteroid injection) compared with eyes assigned to dexamethasone (7%). In the as-assigned analysis, dexamethasone showed superior improvement in macular edema compared with ranibizumab (CST, 34% vs. 19%; P = 0.01), but not compared with methotrexate (CST, 31%; P = 0.59) after being superior to both other regimens at 12 weeks. However, in the censored analysis, only dexamethasone was associated with improvements in macular edema (CST, 34% vs 8% [P < 0.001] and 5% [P < 0.001]) and BCVA improvement of > 5 letters compared with methotrexate and ranibizumab, respectively. Dexamethasone more often was associated with intraocular pressure elevations of ≥ 24 mmHg (32%) and of ≥ 30 mmHg (10%). CONCLUSIONS: Dexamethasone was more effective than methotrexate and ranibizumab for the treatment of persistent or recurrent uveitic macular edema through 24 weeks, with manageable side effects. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Gonzales J, Acharya NR, Sugar EA, et al. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2024. PMID: 39612949. doi:10.1016/j.ophtha.2024.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。